We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.41 | 0.57% | 248.25 | 249.73 | 247.59 | 248.45 | 1,787,707 | 01:00:00 |
From May 2019 to May 2024
By Dave Sebastian
Danaher Corp. (DHR) posted higher earnings in the second quarter as revenue rose.
The Washington-based science and medical technology company earned $708.6 million, or 97 cents a share, meeting expectations of analysts polled by FactSet. The company posted $673.8 million, or 95 cents a share, in profit a year earlier.
Danaher posted adjusted earnings of 99 cents a share. Analysts estimated adjusted per-share earnings of 97 cents.
Revenue for the quarter was $5.16 billion, compared with $4.98 billion in the prior year. A consensus of analysts estimated sales of $5.09 billion.
The company said it expects adjusted per-share earnings for 2019 to be between $4.75 and $4.80. It had previously expected between $4.72 and $4.80.
Thomas Joyce, president and chief executive of Danaher, said in a statement that the company is on track to acquire GE Biopharma and to make an initial public offering on its dental business, which will be called Envista.
Write to at Dave.Sebastian@wsj.com
(END) Dow Jones Newswires
July 18, 2019 06:39 ET (10:39 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
